Key facts
- This page summarizes GSK plc's Form 4 filing for Lyell Immunopharma, Inc. (LYEL).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 23 Jun 2021, 18:14.
GSK plc - 21 Jun 2021 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- LYEL
- Reported as of
- 21 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Jun 2021, 18:14:59 UTC
- Prior SEC filing
- 04 Nov 2022
- Next SEC filing
- 06 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Victoria A. Whyte
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
GSK plc filed Form 4 for Lyell Immunopharma, Inc. (LYEL) on 23 Jun 2021.
Change
- Previous filing in this sequence was filed on 04 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LYEL
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +30,253,189
- Change %
- Price
- Shares after
- 30,253,189
- Date
- 21 Jun 2021
- Ownership
- See Footnote
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LYEL
transaction
Derivative
Series AA Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -30,253,189
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 21 Jun 2021
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 30,253,189
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Series AA Preferred Stock automatically converted into common stock on a 1-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Footnote F2
The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").